Journal for ImmunoTherapy of Cancer

New #JITC article: "Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer" jitc.bmj.com/content/14/5/e…

New #JITC article: "Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers" jitc.bmj.com/content/14/5/e…

New #JITC article: " Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort" jitc.bmj.com/content/14/5/e…

New #JITC article: "Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies" jitc.bmj.com/content/14/5/e… @Vladimi78819357

Congrats to the lab of Dr. David Mooney at @hseas on their new @jitcancer study! 👏 They developed an optimized stem cell-derived #DendriticCell platform that produces scalable, functional cDC-like cells with stronger T-cell priming ability than conventional monocyte-derived DCs for #immunotherapy applications. 🔓 bit.ly/3RBoJy6

New #JITC review: "Immunological consequences of chemotherapy: implications for cancer immunotherapy" jitc.bmj.com/content/14/5/e…

New #JITC article: "KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion" jitc.bmj.com/content/14/5/e…

New #JITC article: "CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer" jitc.bmj.com/content/14/5/e…

New #JITC commentary: "Immune tolerance versus cancer surveillance: an ongoing challenge" jitc.bmj.com/content/14/5/e…

New #JITC article: "Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma" jitc.bmj.com/content/14/5/e…

New #JITC article: "Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy" jitc.bmj.com/content/14/5/e… @kalender_atak @imartincorena @AdamJSchoenfeld @AstraZeneca

New #JITC article: "Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin’s lymphoma" jitc.bmj.com/content/14/5/e…

New #JITC article: "Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer" jitc.bmj.com/content/14/5/e… @garthstrohbehn @VAAnnArbor

New #JITC article: "Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma" jitc.bmj.com/content/14/5/e…

New #JITC editorial: "Local immunotherapy for the treatment of cancer: scientific advances and clinical potential" jitc.bmj.com/content/14/5/e… @DrK4CINJ

Explore Editor-in-Chief Dr. Michael T. Lotze's selection of recent case reports and case series! The May Issue of the #JITC Digest features findings from history, examination and translational investigations. Read the Digest: sitcancer.org/blogs/jitc-pub…

New #JITC article: "Feeder-free generation of functional dendritic cells from human pluripotent stem cells" jitc.bmj.com/content/14/5/e… @WeihungJ

New #JITC article: "First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer" jitc.bmj.com/content/14/5/e…

New #JITC commentary: "Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?" jitc.bmj.com/content/14/5/e…

This study highlights the potential of reprogramming the pancreatic tumor microenvironment to improve immunotherapy response. Approaches like this could help bring more precise and effective treatment options to patients with one of the most challenging cancers. #PGx -AB